Hepatitis B infection: Pathogenesis and management

Journal of Hepatology

Volumn 32, Issue SUPPL.1, 2000, Pages 89-97

  Lok, Anna Suk Fong ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Antiviral therapy; Epidemiology; Hepatitis B; Treatment; Vaccination

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; HEPATITIS B VACCINE; LAMIVUDINE;

BED REST; DNA SYNTHESIS INHIBITION; ERADICATION THERAPY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FAILURE; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; VACCINATION; VIRUS MUTANT;

ANTIBODY FORMATION; ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNE SYSTEM; IMMUNIZATION; LIVER NEOPLASMS; PREVALENCE; VARIATION (GENETICS);

EID: 0002895616     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(00)80418-3     Document Type: Article

References (50)

1. Blumberg BS, Alter HJ, Visnick S. A 'new' antigen in leukemia sera. JAMA 1965; 191: 541-6.
2. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991; 11: 84-92.
3. Szmuness W, Stevens CE, Harley EJ, Zang EA, Alter HJ, Taylor PE, et al. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. New Engl J Med 1982; 307: 1481-6.
4. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336: 196-204.
5. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. New Engl J Med 1997; 336: 1855-9.
6. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336: 325-9.
7. Hsu HY, Chang MH, Ni YH, Lin HH, Wang SM, Chen DS. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 1997; 26: 786-91.
8. Chisari FV Hepatitis B virus transgenic mice: models of viral immunobiology and pathogenesis. Curr Topics Microbiol Immunol 1996; 206: 149-73.
9. Wei Y, Tiollais P. Molecular biology of hepatitis B virus. Clin Liver Dis 1999; 3: 189-219.
10. Summers J, Mason WS. Replication of the genome of a hepatitis like virus by reverse transcription of an RNA intermediate. Cell 1982; 29: 403-15.
11. Lenhoff RJ, Summers J. Coordinate regulation of replication and virus assembly by the large envelope protein of an avian hepadnavirus. J Virol 1994; 68: 4565-71.
12. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997; 71: 9392-9.
13. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996; 93: 4398-402.
14. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999; 29: 1863-9.
15. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; ii: 588-91.
16. Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci USA 1994; 91: 4077-81.
17. Rodriguez-Frias F, Buti M, Jardi R, Cotrina M, Viladomiu L, Esteban R, et al. Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. Hepatology 1995; 22: 1641-7.
18. Carman WF, Trautwein C, van Deursen FJ, Colman K, Dornan E, McIntyre G, et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996; 24: 489-93.
19. Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27: 213-22.
20. Nayersina R, Fowler P, Guilhot S, Missale G, Cerny A, Schlicht HJ, et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 1993; 150: 4659-71.
21. Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996; 98: 1185-94.
22. Rehermann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996; 97: 1655-65.
23. Lok AS. Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis 1992; 10: 46-52.
24. Hsu HY, Chang MH, Lee CY, Chen JS, Hsu HC, Chen DS. Spontaneous loss of HBsAg in children with chronic hepatitis B virus infection. Hepatology 1992; 15: 382-6.
25. Guidotti LG, Chisari FV. To kill or to cure: options in host defense against viral infection. Curr Opin Immunol 1996; 8: 478-83.
26. Davies SE, Portmann BC, O'Grady JG, Aldis PM. Chaggar K, Alexander GJ, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150-7.
27. Beasley RP Hepatitis B virus: the major etiology for hepatocellular carcinoma. Cancer 1988; 61: 1942-56.
28. Matsubara K, Tokino T. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. Mol Biol Med 1990; 7: 243-60.
29. Koshy R, Hofschneider PH. Transactivation by hepatitis B virus may contribute to hepatocarcinogenesis. Curr Topics Microbiol Immunol 1989; 144: 265-81.
30. Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989; 59: 1145-56.
31. Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with interferon alpha. Gastroenterology 1993; 105: 1833-8.
32. De Jongh FE, Janssen H, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630-5.
33. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28: 1669-73.
34. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-23.
35. Lok AS, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-7.
36. Fattovich G, Farci P, Rugge M, Brollo L, Mandas A, Pontisso P, et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992; 15: 584-9.
37. Perrillo R, Tamburro C, Regenstein F, Balart L, Bodenheimer H, Silva M, et al. Low-dose, titratable interferon alpha in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109: 908-16.
38. Sokal EM, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, Goyens P, et al. Interferon alpha therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology. 1998; 114: 988-95.
39. Cohard M, Poynard T, Mathurin P, Zarski JP. Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis. Hepatology 1994; 20: 1390-8.
40. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
41. Heathcote J, Schalm SW, Cianciara J, Farrell G, Feinman V, Shermann M, et al. Lamivudine and intron A combination treatment in patients with chronic hepatitis B infection (abstract). J Hepatol 1998; 29 (Suppl 1): 43.
42. Schiff E, Cianciara J, Kowdley K, Norkans G, Perrillo R, Tong M, et al. and the International Lamivudine Investigator Group. Durability of HBeAg seroconversion after lamivudine monotherapy in controlled phase II and III trials (abstract). Hepatology 1998; 28: 163A.
43. Schiff E, Karayalcin S, Grimm I, Perrillo R, Dienstag J, Husa P, et al. and the International Lamivudine Investigator Group. A placebo controlled study of lamivudine and interferon alpha 2b in patients with chronic hepatitis B who previously failed interferon therapy (abstract). Hepatology 1998; 28: 388A.
44. Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, et al. Lamivudine Transplant Group. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29: 1581-6.
45. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-7.
46. Leung NWY, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Three year lamivudine therapy in chronic HBV (abstract). J Hepatol 1999; 30 (Suppl 1): 59.
47. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CC. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-72.
48. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology. 1999; 29: 889-96.
49. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis virus infection. Hepatology 1999; 29: 971-5.
50. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg positive patients treated with interferon alpha for chronic hepatitis B. N Engl J Med 1996; 334: 1422-7.